Related Experiment Videos
Sulfasalazine and renal tubular function: lack of an effect
Insights
Sulfasalazine (SASP) use in pediatric Crohn's disease patients showed no increased risk of kidney damage. This study found renal function remained normal in children treated with SASP compared to controls.
Area of Science:
- Pediatric Nephrology
- Gastroenterology
- Pharmacology
Background:
- Sulfasalazine (SASP) is a common treatment for pediatric inflammatory bowel disease (IBD), especially Crohn's ileocolitis.
- Concerns exist regarding potential renal tubular damage associated with SASP use.
Purpose of the Study:
- To evaluate the renal tubular function in pediatric patients with Crohn's ileocolitis receiving Sulfasalazine.
- To compare renal function markers between SASP-treated patients and disease-matched controls.
Main Methods:
- Studied 26 pediatric patients (8-18 years) with Crohn's ileocolitis.
- Divided patients into two groups: 13 on SASP treatment and 13 as disease controls.
- Assessed renal tubular function using urinary beta 2-microglobulin and n-acetylglucosaminidase activity.
Main Results:
- Routine renal function tests were normal in all patients.
- Urinary beta 2-microglobulin and n-acetylglucosaminidase levels were within normal limits for both SASP-treated and control groups.
- No significant difference in renal tubular function markers was observed between the groups.
Conclusions:
- Prolonged Sulfasalazine use in pediatric IBD patients does not appear to increase the risk of renal tubular injury.
- Pediatric IBD patients on SASP show comparable renal safety to those not on the medication.
Abstract:
Sulfasalazine (SASP) is frequently used in the treatment of chronic inflammatory bowel disease (IBD), particularly colitis. Because the drug poses a theoretical risk for renal tubular damage, 26 patients, 8-18 years of age, with Crohn's ileocolitis were studied. Thirteen children were receiving SASP while 13 served as disease controls. Renal tubular function was assessed by measurement of urinary beta 2-microglobulin and n-acetylglucosaminidase activity. No abnormalities were found on routine measurement of renal function. Similarly, urinary beta 2-microglobulin and n-acetylglucosaminidase activities were within normal limits for patients receiving SASP, as well as for disease controls. Although there is a theoretical risk for renal tubular damage from the prolonged use of SASP, this study would suggest that IBD patients receiving the drug are at no greater risk for renal injury than their counterparts not receiving the medication.